Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Real Time Quote from BATS)

$14.62 USD

14.62
31,758

+0.16 (1.11%)

Updated Oct 9, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down

by Zacks Equity Research

The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.

Why Is Acadia (ACAD) Down 45% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moving Average Crossover Alert: ACADIA Pharma

by Zacks Equity Research

ACADIA Pharmaceuticals (ACAD) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).

ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA

by Zacks Equity Research

The FDA identifies deficiencies in ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock sinks.

ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.

Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 12.50% and -1.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

Why Is Acadia (ACAD) Up 9.7% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y

by Zacks Equity Research

ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -42.11% and 1.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

TEVA Gears Up to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) third-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products.

Humana (HUM) Gears Up for Q3 Earnings: What Awaits the Stock?

by Zacks Equity Research

Humana's (HUM) third-quarter 2020 results are likely to reflect elevated expenses and lower net investment income, partially offset by a growing membership base.

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio

by Zacks Equity Research

ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.

ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

by Zacks Equity Research

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

by Kinjel Shah

Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.